Neuralink's Blindsight is a sophisticated iteration of existing technology, aimed at restoring limited vision through direct stimulation of the visual cortex, but it is too early to claim that it can enable true sight.
The FDA's 'breakthrough device' designation primarily offers developers a streamlined process and priority review rather than conclusive proof of effectiveness, and Neuralink's device still faces significant challenges.
Collection
[
|
...
]